ReviewFrontiers in immunology2014
T cell responses to viral infections - opportunities for Peptide vaccination.
Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04790240 (The Trial Uses Medicinal Herbs to Direct T Cells to Engulf the COVID-19 Virus and Protect the Organs Well), which is not on this map. Cited by 135 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Trial Uses Medicinal Herbs to Direct T Cells to Engulf the COVID-19 Virus and Protect the Organs Well
Who cites it
135 citing papers in PubMed.
- Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination.Scientific reports · 2023Trial
- T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.Nature medicine · 2021Trial
- Chemical Complementarities of Neuroblastoma Tumor-Resident TCR CDR3s and CMV Antigens are Associated with a Better Outcome.Biochemical genetics · 2026Article
- Anisotropic Gold Nanoconjugates Bearing Immunoinformatically Designed T-Cell Epitope-Containing Peptides: Comparative Evaluation in THP-1 and Human Primary Macrophages.International journal of molecular sciences · 2026Article
- Design of an immunogen containing multidimensionally conserved and immunogenic parts of the HIV proteome.PLoS computational biology · 2026Article
- Article
- TEpiNom: A computational framework integrating population data to prioritize Plasmodium falciparum T cell epitopes.Vaccine · 2026Article
- Proteome-wide curation of experimentally validated HPV T-cell epitopes identifies key gaps in our understanding of cellular immunity to HPV and informs vaccine design.Frontiers in immunology · 2026Article
- T-cell responses to SARS-CoV-2 vaccinations in adults with Down syndrome - a prospective cohort study.Human vaccines & immunotherapeutics · 2025Observational
- Computational Development of Multi-Epitope Reovirus Vaccine with Potent Predicted Binding to TLR2 and TLR4.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Host Immune Response in Chronic Hepatitis Delta: Implications for Pathogenesis and Therapy.Pathogens (Basel, Switzerland) · 2025Review
- Computational Prioritization of T Cell Epitopes to Overcome HLA Restriction and Antigenic Diversity inbioRxiv : the preprint server for biology · 2025Article
- Progress in the development of cancer vaccines for lung cancer utilizing dendritic cells (Review).Oncology letters · 2025Review
- Impact of SARS-CoV-2 on the male reproductive tract: insights from semen analysis and cryopreservation.Journal of assisted reproduction and genetics · 2025Article
- Gold Nanoparticles as a Platform for Delivery of Immunogenic Peptides to THP-1 Derived Macrophages: Insights into Nanotoxicity.Vaccines · 2025Article
- Comprehensive immunoinformatics guided design and in silico assessment of a multi-epitope vaccine to elicit immunity against Mayaro virus.In silico pharmacology · 2025Article
- Influence of Donor-Specific Characteristics on Cytokine Responses in H3N2 Influenza A Virus Infection: New Insights from an Ex Vivo Model.International journal of molecular sciences · 2024Article
- Article
- MHC-Fine: Fine-tuned AlphaFold for precise MHC-peptide complex prediction.Biophysical journal · 2024Article
- Genome-level therapeutic targets identification and chimeric Vaccine designing against theHeliyon · 2024Article
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An effective immune response against viral infections depends on the activation of cytotoxic T cells that can clear infection by killing virus-infected cells. Proper activation of these T cells depends on professional antigen-presenting cells, such as dendritic cells (DCs). In this review, we will discuss the potential of peptide-based vaccines for prevention and treatment of viral diseases. We will describe features of an effective response against both acute and chronic infections, such as an appropriate magnitude, breadth, and quality and discuss requirements for inducing such an effective antiviral immune response. We will address modifications that affect presentation of vaccine components by DCs, including choice of antigen, adjuvants, and formulation. Furthermore, we will describe differences in design between preventive and therapeutic peptide-based vaccines. The ultimate goal in the design of preventive vaccines is to develop a universal vaccine that cross-protects against multiple strains of the virus. For therapeutic vaccines, cross-protection is of less importance, but enhancing existing T cell responses is essential. Although peptide vaccination is successful in inducing responses in human papillomavirus (HPV) infected patients, there are still several challenges such as choosing the right target epitopes, choosing safe adjuvants that improve immunogenicity of these epitopes, and steering the immune response in the desired direction. We will conclude with an overview of the current status of peptide vaccination, hurdles to overcome, and prospects for the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.